Intrinsic value of Dermira - DERM

Previous Close

$10.13

  Intrinsic Value

$3.52

stock screener

  Rating & Target

str. sell

-65%

Previous close

$10.13

 
Intrinsic value

$3.52

 
Up/down potential

-65%

 
Rating

str. sell

We calculate the intrinsic value of DERM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  7
  11
  17
  24
  34
  47
  63
  83
  107
  135
  168
  205
  248
  295
  346
  403
  464
  530
  600
  675
  754
  837
  924
  1,015
  1,111
  1,210
  1,313
  1,421
  1,533
  1,649
Variable operating expenses, $m
  36
  56
  83
  121
  171
  234
  315
  413
  531
  671
  833
  1,019
  1,228
  1,461
  1,718
  1,998
  2,302
  2,628
  2,976
  3,346
  3,737
  4,149
  4,581
  5,034
  5,506
  5,999
  6,512
  7,046
  7,601
  8,178
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  36
  56
  83
  121
  171
  234
  315
  413
  531
  671
  833
  1,019
  1,228
  1,461
  1,718
  1,998
  2,302
  2,628
  2,976
  3,346
  3,737
  4,149
  4,581
  5,034
  5,506
  5,999
  6,512
  7,046
  7,601
  8,178
Operating income, $m
  -29
  -45
  -67
  -97
  -136
  -187
  -251
  -330
  -424
  -536
  -665
  -813
  -980
  -1,166
  -1,371
  -1,595
  -1,838
  -2,098
  -2,376
  -2,671
  -2,984
  -3,312
  -3,657
  -4,019
  -4,396
  -4,789
  -5,199
  -5,625
  -6,068
  -6,529
EBITDA, $m
  -28
  -44
  -66
  -95
  -134
  -185
  -248
  -326
  -419
  -529
  -657
  -804
  -969
  -1,152
  -1,355
  -1,576
  -1,816
  -2,073
  -2,348
  -2,639
  -2,948
  -3,273
  -3,614
  -3,970
  -4,343
  -4,732
  -5,137
  -5,558
  -5,996
  -6,451
Interest expense (income), $m
  0
  16
  1
  6
  12
  21
  33
  48
  68
  91
  119
  153
  192
  236
  286
  342
  403
  470
  543
  621
  705
  793
  887
  985
  1,089
  1,197
  1,310
  1,428
  1,551
  1,678
  1,811
Earnings before tax, $m
  -45
  -46
  -72
  -109
  -157
  -220
  -300
  -397
  -515
  -655
  -818
  -1,005
  -1,216
  -1,452
  -1,713
  -1,999
  -2,308
  -2,641
  -2,997
  -3,376
  -3,777
  -4,199
  -4,643
  -5,107
  -5,593
  -6,099
  -6,627
  -7,176
  -7,747
  -8,340
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -45
  -46
  -72
  -109
  -157
  -220
  -300
  -397
  -515
  -655
  -818
  -1,005
  -1,216
  -1,452
  -1,713
  -1,999
  -2,308
  -2,641
  -2,997
  -3,376
  -3,777
  -4,199
  -4,643
  -5,107
  -5,593
  -6,099
  -6,627
  -7,176
  -7,747
  -8,340

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  165
  255
  382
  554
  781
  1,074
  1,441
  1,892
  2,435
  3,076
  3,819
  4,670
  5,628
  6,697
  7,874
  9,160
  10,551
  12,046
  13,643
  15,339
  17,132
  19,019
  21,000
  23,074
  25,240
  27,499
  29,851
  32,298
  34,843
  37,487
Adjusted assets (=assets-cash), $m
  165
  255
  382
  554
  781
  1,074
  1,441
  1,892
  2,435
  3,076
  3,819
  4,670
  5,628
  6,697
  7,874
  9,160
  10,551
  12,046
  13,643
  15,339
  17,132
  19,019
  21,000
  23,074
  25,240
  27,499
  29,851
  32,298
  34,843
  37,487
Revenue / Adjusted assets
  0.042
  0.043
  0.045
  0.043
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
  0.044
Average production assets, $m
  3
  5
  7
  11
  15
  21
  28
  37
  48
  60
  75
  92
  110
  131
  155
  180
  207
  236
  268
  301
  336
  373
  412
  453
  495
  540
  586
  634
  684
  736
Working capital, $m
  -146
  -226
  -338
  -490
  -691
  -950
  -1,275
  -1,674
  -2,154
  -2,721
  -3,379
  -4,131
  -4,980
  -5,925
  -6,966
  -8,104
  -9,335
  -10,658
  -12,070
  -13,571
  -15,157
  -16,827
  -18,579
  -20,414
  -22,330
  -24,328
  -26,409
  -28,574
  -30,826
  -33,165
Total debt, $m
  17
  98
  212
  366
  571
  835
  1,165
  1,571
  2,060
  2,636
  3,306
  4,071
  4,934
  5,895
  6,955
  8,112
  9,364
  10,710
  12,147
  13,673
  15,287
  16,986
  18,769
  20,635
  22,584
  24,617
  26,734
  28,937
  31,227
  33,607
Total liabilities, $m
  149
  230
  343
  498
  703
  966
  1,297
  1,703
  2,192
  2,768
  3,438
  4,203
  5,066
  6,027
  7,087
  8,244
  9,496
  10,842
  12,279
  13,805
  15,419
  17,117
  18,900
  20,767
  22,716
  24,749
  26,866
  29,068
  31,358
  33,739
Total equity, $m
  17
  26
  38
  55
  78
  107
  144
  189
  244
  308
  382
  467
  563
  670
  787
  916
  1,055
  1,205
  1,364
  1,534
  1,713
  1,902
  2,100
  2,307
  2,524
  2,750
  2,985
  3,230
  3,484
  3,749
Total liabilities and equity, $m
  166
  256
  381
  553
  781
  1,073
  1,441
  1,892
  2,436
  3,076
  3,820
  4,670
  5,629
  6,697
  7,874
  9,160
  10,551
  12,047
  13,643
  15,339
  17,132
  19,019
  21,000
  23,074
  25,240
  27,499
  29,851
  32,298
  34,842
  37,488
Debt-to-equity ratio
  1.020
  3.840
  5.550
  6.620
  7.310
  7.770
  8.090
  8.300
  8.460
  8.570
  8.660
  8.720
  8.770
  8.800
  8.830
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.960
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -45
  -46
  -72
  -109
  -157
  -220
  -300
  -397
  -515
  -655
  -818
  -1,005
  -1,216
  -1,452
  -1,713
  -1,999
  -2,308
  -2,641
  -2,997
  -3,376
  -3,777
  -4,199
  -4,643
  -5,107
  -5,593
  -6,099
  -6,627
  -7,176
  -7,747
  -8,340
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  2
  2
  3
  4
  5
  7
  8
  10
  12
  14
  16
  19
  22
  25
  28
  32
  36
  40
  44
  48
  53
  57
  62
  67
  73
  78
Funds from operations, $m
  -45
  -45
  -71
  -108
  -156
  -218
  -296
  -393
  -510
  -649
  -810
  -995
  -1,205
  -1,439
  -1,697
  -1,980
  -2,286
  -2,616
  -2,969
  -3,344
  -3,741
  -4,159
  -4,599
  -5,059
  -5,540
  -6,042
  -6,564
  -7,108
  -7,674
  -8,262
Change in working capital, $m
  -55
  -80
  -112
  -152
  -201
  -259
  -325
  -399
  -480
  -567
  -658
  -752
  -848
  -945
  -1,042
  -1,137
  -1,231
  -1,323
  -1,413
  -1,500
  -1,586
  -1,670
  -1,753
  -1,835
  -1,916
  -1,998
  -2,081
  -2,165
  -2,251
  -2,340
Cash from operations, $m
  10
  35
  41
  45
  46
  41
  29
  6
  -30
  -82
  -152
  -243
  -356
  -493
  -655
  -842
  -1,055
  -1,293
  -1,556
  -1,844
  -2,155
  -2,489
  -2,846
  -3,224
  -3,624
  -4,044
  -4,483
  -4,943
  -5,423
  -5,922
Maintenance CAPEX, $m
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -12
  -14
  -16
  -19
  -22
  -25
  -28
  -32
  -36
  -40
  -44
  -48
  -53
  -57
  -62
  -67
  -73
New CAPEX, $m
  -1
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -11
  -13
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -39
  -41
  -43
  -44
  -46
  -48
  -50
  -52
Cash from investing activities, $m
  -1
  -2
  -3
  -4
  -5
  -8
  -9
  -12
  -15
  -18
  -21
  -25
  -29
  -33
  -37
  -41
  -46
  -51
  -56
  -61
  -67
  -73
  -79
  -85
  -91
  -97
  -103
  -110
  -117
  -125
Free cash flow, $m
  9
  33
  37
  41
  40
  34
  19
  -6
  -45
  -100
  -173
  -268
  -385
  -526
  -692
  -884
  -1,101
  -1,344
  -1,613
  -1,905
  -2,222
  -2,562
  -2,925
  -3,309
  -3,714
  -4,141
  -4,587
  -5,053
  -5,540
  -6,047
Issuance/(repayment) of debt, $m
  -263
  81
  114
  155
  205
  263
  331
  406
  488
  577
  669
  765
  863
  961
  1,060
  1,157
  1,252
  1,346
  1,437
  1,526
  1,613
  1,699
  1,783
  1,866
  1,949
  2,033
  2,117
  2,203
  2,290
  2,380
Issuance/(repurchase) of shares, $m
  358
  55
  85
  126
  180
  250
  336
  443
  570
  719
  892
  1,090
  1,312
  1,559
  1,831
  2,127
  2,447
  2,791
  3,157
  3,546
  3,956
  4,388
  4,841
  5,315
  5,809
  6,325
  6,862
  7,420
  8,001
  8,605
Cash from financing (excl. dividends), $m  
  95
  136
  199
  281
  385
  513
  667
  849
  1,058
  1,296
  1,561
  1,855
  2,175
  2,520
  2,891
  3,284
  3,699
  4,137
  4,594
  5,072
  5,569
  6,087
  6,624
  7,181
  7,758
  8,358
  8,979
  9,623
  10,291
  10,985
Total cash flow (excl. dividends), $m
  105
  168
  236
  321
  425
  547
  686
  843
  1,013
  1,196
  1,389
  1,587
  1,790
  1,995
  2,198
  2,400
  2,598
  2,792
  2,981
  3,166
  3,347
  3,524
  3,699
  3,872
  4,044
  4,217
  4,392
  4,569
  4,751
  4,938
Retained Cash Flow (-), $m
  -358
  -55
  -85
  -126
  -180
  -250
  -336
  -443
  -570
  -719
  -892
  -1,090
  -1,312
  -1,559
  -1,831
  -2,127
  -2,447
  -2,791
  -3,157
  -3,546
  -3,956
  -4,388
  -4,841
  -5,315
  -5,809
  -6,325
  -6,862
  -7,420
  -8,001
  -8,605
Prev. year cash balance distribution, $m
  446
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  193
  114
  151
  195
  245
  297
  350
  400
  444
  477
  496
  497
  478
  435
  367
  273
  151
  1
  -176
  -379
  -609
  -863
  -1,142
  -1,443
  -1,765
  -2,108
  -2,470
  -2,851
  -3,250
  -3,666
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  185
  104
  132
  161
  190
  216
  237
  250
  255
  250
  236
  212
  182
  146
  108
  69
  33
  0
  -27
  -48
  -63
  -72
  -75
  -73
  -69
  -61
  -53
  -44
  -35
  -28
Current shareholders' claim on cash, %
  50.0
  23.1
  10.6
  4.9
  2.3
  1.1
  0.5
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

FINANCIAL RATIOS  of  Dermira (DERM)

Valuation Ratios
P/E Ratio -4.1
Price to Sales 15.7
Price to Book 1.5
Price to Tangible Book
Price to Cash Flow -4.9
Price to Free Cash Flow -4.8
Growth Rates
Sales Growth Rate 228.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -33.3%
Ret/ On Assets - 3 Yr. Avg. -34.5%
Return On Total Capital -41.2%
Ret/ On T. Cap. - 3 Yr. Avg. -41.7%
Return On Equity -41.2%
Return On Equity - 3 Yr. Avg. -42.1%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -387%
EBITDA Margin - 3 Yr. Avg. -657.6%
Operating Margin -391.3%
Oper. Margin - 3 Yr. Avg. -663.8%
Pre-Tax Margin -387%
Pre-Tax Margin - 3 Yr. Avg. -657.6%
Net Profit Margin -387%
Net Profit Margin - 3 Yr. Avg. -652.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0.4%
Payout Ratio 0%

DERM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DERM stock intrinsic value calculation we used $4.541 million for the last fiscal year's total revenue generated by Dermira. The default revenue input number comes from 0001 income statement of Dermira. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DERM stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DERM is calculated based on our internal credit rating of Dermira, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Dermira.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DERM stock the variable cost ratio is equal to 500%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for DERM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.8% for Dermira.

Corporate tax rate of 27% is the nominal tax rate for Dermira. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DERM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DERM are equal to 44.6%.

Life of production assets of 9.4 years is the average useful life of capital assets used in Dermira operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DERM is equal to -2010.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $149.649 million for Dermira - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 41.848 million for Dermira is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Dermira at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
ABBV AbbVie 90.14 174.70  str.buy
RVNC Revance Therap 20.99 9.01  str.sell
GSK GlaxoSmithKlin 40.41 350.10  str.buy
MRK Merck&Co 74.84 33.05  str.sell
LLY Eli Lilly 112.20 67.15  sell
JNJ Johnson&Johnso 144.50 176.79  buy

COMPANY NEWS

▶ Dermira: 2Q Earnings Snapshot   [05:02PM  Associated Press]
▶ Dermira Shares Soar With FDA Approval of New Cloth   [Jun-29-18 12:00PM  TheStreet.com]
▶ Here's Why Dermira Inc Stock Fell More Than 23% Today   [May-24-18 04:18PM  Motley Fool]
▶ Schlumberger Is Among 7 Stocks Ready to Change Direction   [May-14-18 02:10PM  TheStreet.com]
▶ Dermira: 1Q Earnings Snapshot   [May-03-18 05:58PM  Associated Press]
▶ Your first trade for Friday, March 9   [Mar-09-18 09:09AM  CNBC]
▶ Why This Biotech Stock Just Lost Two-Thirds Of Its Value   [04:13PM  Investor's Business Daily]
▶ US Stocks Reverse Losses   [03:07PM  GuruFocus.com]
▶ Dermira reports 4Q loss   [Feb-23-18 05:00AM  Associated Press]
▶ ETFs with exposure to Dermira, Inc. : December 28, 2017   [Dec-28-17 12:02PM  Capital Cube]
▶ Dermira Inc (DERM): What Are The Future Prospects?   [Nov-28-17 04:26PM  Simply Wall St.]
▶ Dermira reports 3Q loss   [Nov-06-17 04:49PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.